NYPOZI C Code: C9173

Drug & Product Overview

HCPCS Descriptor Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram

HCPCS Added Date January 1, 2025

Manufacturer Tanvex Biopharma USA

Route of Administration Intravenous, Subcutaneous

Generic Status HCPCS Discontinued

Dosage Type Single-Dose

Dosage Form Injection

About NYPOZI

Nypozi is a medication aligned to the HCPCS C Code: C9173 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous or subcutaneous routes and manufactured by Tanvex Biopharma USA.

Manufacturers, reach out to us to add more information.

NDC Code Information

4 NDC packages are crosswalked to C9173. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	NYPOZI
	NYPOZI
	NYPOZI
	NYPOZI

Login to view 4 NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Biosimilar Information

NYPOZI Approval Date: June 28, 2024

Product Name	HCPCS Code	Active Ingredient	BLA Type
Neupogen	J1442	Filgrastim	351(a) Originator Product
Zarxio	Q5101	Filgrastim	351(k) Biosimilar
Nivestym	Q5110	Filgrastim	351(k) Biosimilar
Releuko	C9096	Filgrastim	351(k) Biosimilar
Nypozi	C9173	Filgrastim	351(k) Biosimilar
Filkri	N/A	Filgrastim	351(k) Biosimilar

NYPOZI CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

NYPOZI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute myeloid leukemia receiving induction or consolidation chemotherapy Autologous peripheral blood progenitor cell collection and therapy Hematopoietic Syndrome of Acute Radiation Syndrome Nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs Nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation Severe chronic neutropenia – congenital neutropenia Severe chronic neutropenia – idiopathic or cyclic neutropenia

Drug Class

Granulocyte Colony-Stimulating Factor [CS]Increased Myeloid Cell Production [PE]Leukocyte Growth Factor [EPC]

Frequently Asked Questions

Is there an available NYPOZI billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for NYPOZI.

What are the available NYPOZI patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for NYPOZI.

Where can I find NYPOZI prescribing information?

NYPOZI prescribing information can be found at the link below. Visit Here →

Where can I find NYPOZI side effect information?

Our team has not identified a source of side effect information for NYPOZI

Does billing NYPOZI require JZ/JW wastage modifiers?

CMS does not include NYPOZI (C9173) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing C9173. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.